Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity
- 23 July 2009
- journal article
- case report
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46 (2) , 173-175
- https://doi.org/10.1016/j.jcv.2009.06.020
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on IntegraseJournal of Biological Chemistry, 2009
- Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2009
- Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimenAIDS, 2008
- HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitroJournal of Antimicrobial Chemotherapy, 2008
- Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 PatientsAIDS Research and Human Retroviruses, 2008
- Raltegravir treatment response in an HIV-2 infected patient: a case reportAIDS, 2008
- Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patientsAIDS, 2008
- Ile178 of HIV-1 reverse transcriptase is critical for inhibiting the viral integraseBiochemical and Biophysical Research Communications, 2007
- Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2006
- Natural resistance of human immunodeficiency virus type 2 to zidovudineVirology, 2005